drugset / Trial / NCT01441882
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2
Completed
19 enrolled
OHSU Knight Cancer Institute
Oregon Health and Science University · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well dasatinib works in treating patients with chronic lymphocytic leukemia (CLL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2011-10
- Primary completion
- 2016-07-12
- Completion
- 2018-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | — | Oral |